Here's why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today

Kazia's investigational drug, Paxalisib, is set to be involved in its ninth ongoing clinical study.

Shares in Kazia Therapeutics Ltd (ASX: KZA) lifted today after news its investigational drug Paxalisib will be part of another study for the treatment of brain cancer. At market close, the Kazia share price is $1.40 – 6.87% higher than its previous closing price.

The investigation will see Kazia partnering with US-based Joan & Sanford I Weill Medical College at Cornell University in New York.

The two organisations will launch a phase II clinical study combining Paxalisib with ketogenesis, the body's own metabolic process in breaking down fatty acids.

Kazia states the combination has the potential to treat symptoms of glioblastoma, a common and aggressive type of brain cancer.

It's the ninth ongoing clinical study to involve Paxalisib.

Two staff in a medical research laboratory wearing masks and caps work on their tests, representing the performance of ASX healthcare shares in FY22

Image Source: Getty Images

New clinical study

Paxalisib has been developed as a treatment for glioblastoma. The drug is an inhibitor of the brain-penetrant PI3K pathway. Blocking the pathway has so far shown to effectively treat glioblastoma.

In the newly announced clinical trial, Paxalisib is being combined with the human body's response to the 'ketogenic diet'. It sees the body using proteins and fats instead of glucose as fuel for energy.

In metabolising fats and proteins, the human body breaks them down into ketones.

Tumour cells can't metabolise ketones well, so cancers can effectively 'starve' on a ketogenic diet. The ketogenic diet also enhances the PI3K pathway.

Trial participants will also be given metformin, a drug that lowers insulin levels. Insulin has been shown to also enhance the PI3K pathway.

The study will involve around 32 patients. Of those, 16 will have previously been unsuccessfully treated with standard-of-care treatments for glioblastoma. The other 16 will have not only have undergone unsuccessful standard treatment, but their glioblastomas will have progressed through their treatment.

The primary endpoint will be progression-free survival at six months. The study will take approximately two years to complete.

Kazia will provide the drug and a financial grant for the study.

Kazia Therapeutics share price snapshot

The Kazia Therapeutics share price is performing well on the ASX lately.

Currently, it's 20% higher than it was at the start of 2021. It's also gained 250% since this time last year.

The company has a market capitalisation of around $185 million, with approximately 129 million shares outstanding.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »